FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620649449> ?p ?o ?g. }

• W2620649449 endingPage "3772" @default.
• W2620649449 startingPage "3764" @default.
• W2620649449 abstract "DTaP5-IPV-HB-Hib vaccine is a fully-liquid, combination hexavalent vaccine. This phase III, open-label, multicentre study conducted in Spain, evaluated the immune response to all DTaP5-IPV-HB-Hib antigens when the vaccine was used in a mixed hexa/penta/hexa primary series. Infants (who had received one dose of hepatitis B vaccine at birth) received a mixed schedule including DTaP5-IPV-HB-Hib (PRP-OMP conjugate) at 2 and 6 months of age, DTaP5-IPV-Hib at 4 months, meningococcal serogroup C conjugate (MCC) vaccine at 2 and 4 months, and routine rotavirus and pneumococcal vaccination. One month post-dose 3 of the mixed schedule, response rates were considered acceptable if the lower bound of the two-sided 95% confidence interval around the post-vaccination response rate was >90% for hepatitis B and >80% for Haemophilus influenzae type b (Hib). Secondary immunogenicity objectives included description of the antibody response to all hexavalent antigens one month after completion of the mixed schedule, and to MCC antigen one month after the second MCC dose. The safety profile after each dose of study vaccine was described. Of 385 healthy infants enrolled, 384 completed the study. The primary objective was achieved for both hepatitis B and Hib; the lower bound of the 2-sided 95% CI of the response rates (97.2% and 99.0%, respectively) were greater than the pre-specified acceptability thresholds. One month post-dose 3 of the mixed schedule, all participants were seroprotected against diphtheria, tetanus and polio. The mixed schedule induced a robust immune response to all hexavalent antigens. The co-administration of the hexavalent vaccine in a mixed schedule with MCC vaccine did not reduce the immune response to vaccine antigens. Vaccines were well tolerated. In conclusion, the acceptability of response rates against Hib and hepatitis B were demonstrated one month post-dose 3 of the mixed schedule; robust immune responses against all other hexavalent antigens were observed. clinicaltrial.gov: NCT01839188; EudraCT: 2012-004221-25" @default.
• W2620649449 created "2017-06-09" @default.
• W2620649449 creator A5005538917 @default.
• W2620649449 creator A5053121427 @default.
• W2620649449 creator A5061717948 @default.
• W2620649449 creator A5062757576 @default.
• W2620649449 creator A5079289417 @default.
• W2620649449 date "2017-06-01" @default.
• W2620649449 modified "2023-09-27" @default.
• W2620649449 title "Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib)" @default.
• W2620649449 cites W1533521320 @default.
• W2620649449 cites W1912692997 @default.
• W2620649449 cites W1967704991 @default.
• W2620649449 cites W1979841030 @default.
• W2620649449 cites W1981573468 @default.
• W2620649449 cites W1994429673 @default.
• W2620649449 cites W2002144815 @default.
• W2620649449 cites W2004239384 @default.
• W2620649449 cites W2034768197 @default.
• W2620649449 cites W2040556080 @default.
• W2620649449 cites W2048649102 @default.
• W2620649449 cites W2054922301 @default.
• W2620649449 cites W2075980253 @default.
• W2620649449 cites W2086311575 @default.
• W2620649449 cites W2168867739 @default.
• W2620649449 cites W2170297115 @default.
• W2620649449 cites W2170308370 @default.
• W2620649449 cites W2267384356 @default.
• W2620649449 cites W2409187977 @default.
• W2620649449 cites W2550976356 @default.
• W2620649449 cites W2551638189 @default.
• W2620649449 cites W2096600371 @default.
• W2620649449 doi "https://doi.org/10.1016/j.vaccine.2017.05.043" @default.
• W2620649449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28583305" @default.
• W2620649449 hasPublicationYear "2017" @default.
• W2620649449 type Work @default.
• W2620649449 sameAs 2620649449 @default.
• W2620649449 citedByCount "12" @default.
• W2620649449 countsByYear W26206494492017 @default.
• W2620649449 countsByYear W26206494492018 @default.
• W2620649449 countsByYear W26206494492019 @default.
• W2620649449 countsByYear W26206494492020 @default.
• W2620649449 countsByYear W26206494492021 @default.
• W2620649449 countsByYear W26206494492022 @default.
• W2620649449 countsByYear W26206494492023 @default.
• W2620649449 crossrefType "journal-article" @default.
• W2620649449 hasAuthorship W2620649449A5005538917 @default.
• W2620649449 hasAuthorship W2620649449A5053121427 @default.
• W2620649449 hasAuthorship W2620649449A5061717948 @default.
• W2620649449 hasAuthorship W2620649449A5062757576 @default.
• W2620649449 hasAuthorship W2620649449A5079289417 @default.
• W2620649449 hasConcept C147483822 @default.
• W2620649449 hasConcept C187212893 @default.
• W2620649449 hasConcept C203014093 @default.
• W2620649449 hasConcept C22070199 @default.
• W2620649449 hasConcept C2522874641 @default.
• W2620649449 hasConcept C2777382497 @default.
• W2620649449 hasConcept C2777410769 @default.
• W2620649449 hasConcept C2777704310 @default.
• W2620649449 hasConcept C2779583294 @default.
• W2620649449 hasConcept C2779592421 @default.
• W2620649449 hasConcept C2779841045 @default.
• W2620649449 hasConcept C2780572238 @default.
• W2620649449 hasConcept C2780593183 @default.
• W2620649449 hasConcept C2780868878 @default.
• W2620649449 hasConcept C2781037505 @default.
• W2620649449 hasConcept C71924100 @default.
• W2620649449 hasConceptScore W2620649449C147483822 @default.
• W2620649449 hasConceptScore W2620649449C187212893 @default.
• W2620649449 hasConceptScore W2620649449C203014093 @default.
• W2620649449 hasConceptScore W2620649449C22070199 @default.
• W2620649449 hasConceptScore W2620649449C2522874641 @default.
• W2620649449 hasConceptScore W2620649449C2777382497 @default.
• W2620649449 hasConceptScore W2620649449C2777410769 @default.
• W2620649449 hasConceptScore W2620649449C2777704310 @default.
• W2620649449 hasConceptScore W2620649449C2779583294 @default.
• W2620649449 hasConceptScore W2620649449C2779592421 @default.
• W2620649449 hasConceptScore W2620649449C2779841045 @default.
• W2620649449 hasConceptScore W2620649449C2780572238 @default.
• W2620649449 hasConceptScore W2620649449C2780593183 @default.
• W2620649449 hasConceptScore W2620649449C2780868878 @default.
• W2620649449 hasConceptScore W2620649449C2781037505 @default.
• W2620649449 hasConceptScore W2620649449C71924100 @default.
• W2620649449 hasIssue "30" @default.
• W2620649449 hasLocation W26206494491 @default.
• W2620649449 hasLocation W26206494492 @default.
• W2620649449 hasOpenAccess W2620649449 @default.
• W2620649449 hasPrimaryLocation W26206494491 @default.
• W2620649449 hasRelatedWork W1658079230 @default.
• W2620649449 hasRelatedWork W1984666797 @default.
• W2620649449 hasRelatedWork W1999639125 @default.
• W2620649449 hasRelatedWork W2019593677 @default.
• W2620649449 hasRelatedWork W2021320116 @default.
• W2620649449 hasRelatedWork W2092600119 @default.
• W2620649449 hasRelatedWork W212340933 @default.
• W2620649449 hasRelatedWork W2142872869 @default.
• W2620649449 hasRelatedWork W2184929555 @default.
• W2620649449 hasRelatedWork W2753327877 @default.

• next